Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Policy

Bill Addresses Endocrine Disrupters

by Britt E. Erickson
December 14, 2009 | A version of this story appeared in Volume 87, Issue 50

Rep. Jim Moran (D-Va.) and Sen. John Kerry (D-Mass.) introduced joint legislation on Dec. 3 to examine links between endocrine-disrupting chemicals in consumer products and the increase in hormone-related disorders, such as diabetes, obesity, breast cancer, prostate cancer, and autism. The Endocrine Disruption Prevention Act of 2009 (H.R. 4190, S. 2828) authorizes the National Institute of Environmental Health Sciences to develop a research program and establish an independent panel of scientists to prioritize which chemicals to investigate for their ability to disrupt the endocrine system. If a chemical presents any concern to the panel, the bill would require the relevant federal agency to propose the next steps to Congress within six months. The bill addresses inadequacies in EPA's Endocrine Disrupter Screening Program, which launched in October after more than a decade of delays. EPA's program will initially test 67 pesticide chemicals with methods that are considered outdated by many experts.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.